Michael Rothrock, MBA, MHA, and H. Eric Cannon, PharmD, FAMCP, open a discussion surrounding payer considerations relating to the treatment of major depressive disorder (MDD).
Michael Rothrock, MBA, MHA: When we talk about the biggest unmet needs among the treatment options for MDD [major depressive disorder], a few things stick out. We’re looking for new mechanisms of action and, more important, quicker onsets of action. We want patients to get a high response in the shortest time possible. Even though most drugs are generic and very inexpensive, they could take up to 8 weeks to show benefit. We’re looking for higher response rates, a shorter onset of action, and a longer durability of benefit, with improved tolerability and adverse effects.
H. Eric Cannon, PharmD, FAMCP: The reality is that patients are waiting. With COVID-19, we had all kinds of delays, so we need to have treatments that quickly start to show some benefit. The full benefit won’t happen immediately, but patients are in a bad way right now. The faster we can get the onset, the easier it is for us to identify appropriate treatments. Those are the 2 big unmet needs.
Transcript edited for clarity.
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More